Added to YB: 2024-09-26
Pitch date: 2024-09-23
AVTE [bullish]
Aerovate Therapeutics, Inc.
+37.44%
current return
Author Info
Clark Street Value is a special sits/event-driven investor. Sign up for the newsletter.
Company Info
As of April 28, 2025, Aerovate Therapeutics, Inc. was acquired by Jade Biosciences, Inc., in a reverse merger transaction.
Market Cap
$77.7M
Pitch Price
$7.13
Price Target
2.92 (-70%)
Dividend
N/A
EV/EBITDA
-0.03
P/E
-1.58
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Aerovate Therapeutics: Broken Biotech, Shell Company? Potential Liquidation
AVTE: Failed PAH drug trial, 78% layoffs. Exploring strategic alternatives, including liquidation. Only product candidate. New SEC shell company rule may impact. Est. liquidation value $2.92/share vs $1.71 price. RA Capital owns 32%, successful reverse merger track record.
Read full article (3 min)